Unified Platform Serves as an eSource for a COVID Treatment Trial

Date Published:
Case Study

An emerging biopharmaceutical company utilized multiple solutions with Signant SmartSignals Unified Platform to conduct a phase II trial of a COVID treatment in critically ill patients, optimizing technology to meet the unique challenges of the trial and population.

See how our fully-integrated solution was implemented two weeks faster than the proposed timeline, while taking into account all the study needs, including eSource data capture.

Download Now